Literature DB >> 10553079

Defects in the generation of IFN-gamma are overcome to control infection with Leishmania donovani in CC chemokine receptor (CCR) 5-, macrophage inflammatory protein-1 alpha-, or CCR2-deficient mice.

N Sato1, W A Kuziel, P C Melby, R L Reddick, V Kostecki, W Zhao, N Maeda, S K Ahuja, S S Ahuja.   

Abstract

We investigated the immune responses in mice lacking CCR2, CCR5, or macrophage inflammatory protein-1 alpha (MIP-1 alpha), a ligand for CCR5, in two situations: following T cell stimulation or after challenge with Leishmania donovani, an intracellular microbe whose control is dependent on a Th1 immune response. Mice deficient in CCR5, MIP-1 alpha, or CCR2 had reduced IFN-gamma responses following ligation of the TCR. Reduced IFN-gamma responses following PMA and ionomycin were also observed in CD8+ T cells of CCR5-/- and CCR2-/- mice. During the early phases of infection, all three knockout mice had low Ag-specific IFN-gamma responses. However, this reduced IFN-gamma response was overcome during a state of persistent Ag stimulation (chronic infection), and was not associated with an adverse parasitologic outcome in any of the gene-targeted mouse strains. To the contrary, during the late phase of infection, an exaggerated Ag-specific IFN-gamma response was evident in CCR5-/- and MIP-1 alpha-/- mice, and this correlated with an enhanced control of parasite replication. Although granuloma formation was abnormal in each of the knockout mice, there was no correlation between the number or architecture of the granulomas and parasite burden. Collectively, these findings indicate an important role for CCR5, MIP-1 alpha, and CCR2 in granulomatous inflammation, and that CCR5 and MIP-1 alpha, possibly acting through CCR5, might play a deleterious role in the outcome of chronic L. donovani infection. Our data also suggest that there might be cross-talk between TCR and chemokine receptor signaling pathways.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10553079

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  52 in total

Review 1.  Gene targeting of chemokines and their receptors.

Authors:  D M Slattery; N Gerard; C Gerard
Journal:  Springer Semin Immunopathol       Date:  2000

2.  Impaired lung dendritic cell activation in CCR2 knockout mice.

Authors:  Bo-Chin Chiu; Christine M Freeman; Valerie R Stolberg; Jerry S Hu; Kyriaki Zeibecoglou; Bao Lu; Craig Gerard; Israel F Charo; Sergio A Lira; Stephen W Chensue
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

3.  The role of MIP-1alpha in experimental hypersensitivity pneumonitis.

Authors:  M Schuyler; K Gott; V French
Journal:  Lung       Date:  2004       Impact factor: 2.584

Review 4.  Genetics of sarcoidosis: candidate genes and genome scans.

Authors:  Michael C Iannuzzi; Benjamin A Rybicki
Journal:  Proc Am Thorac Soc       Date:  2007-01

5.  Chemokine receptor 2 serves an early and essential role in resistance to Mycobacterium tuberculosis.

Authors:  W Peters; H M Scott; H F Chambers; J L Flynn; I F Charo; J D Ernst
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

6.  Regulatory T-Cell Dynamics in Cutaneous and Mucocutaneous Leishmaniasis due to Leishmania braziliensis.

Authors:  Nicolas Barros; Nestor Vasquez; Fernando Woll; Cesar Sanchez; Braulio Valencia; Alejandro Llanos-Cuentas; A Clinton White; Martin Montes
Journal:  Am J Trop Med Hyg       Date:  2018-02-01       Impact factor: 2.345

7.  The CC chemokine receptor 5 is important in control of parasite replication and acute cardiac inflammation following infection with Trypanosoma cruzi.

Authors:  Jenny L Hardison; Ruth A Wrightsman; Philip M Carpenter; William A Kuziel; Thomas E Lane; Jerry E Manning
Journal:  Infect Immun       Date:  2006-01       Impact factor: 3.441

8.  Double-edged genetic swords and immunity: lesson from CCR5 and beyond.

Authors:  Sunil K Ahuja; Weijing He
Journal:  J Infect Dis       Date:  2010-01-15       Impact factor: 5.226

9.  SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo.

Authors:  J M Strizki; S Xu; N E Wagner; L Wojcik; J Liu; Y Hou; M Endres; A Palani; S Shapiro; J W Clader; W J Greenlee; J R Tagat; S McCombie; K Cox; A B Fawzi; C C Chou; C Pugliese-Sivo; L Davies; M E Moreno; D D Ho; A Trkola; C A Stoddart; J P Moore; G R Reyes; B M Baroudy
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-16       Impact factor: 11.205

10.  Immune-mediated regression of established B16F10 melanoma by intratumoral injection of attenuated Toxoplasma gondii protects against rechallenge.

Authors:  Jason R Baird; Katelyn T Byrne; Patrick H Lizotte; Seiko Toraya-Brown; Uciane K Scarlett; Matthew P Alexander; Mee Rie Sheen; Barbara A Fox; David J Bzik; Marcus Bosenberg; David W Mullins; Mary Jo Turk; Steven Fiering
Journal:  J Immunol       Date:  2012-12-07       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.